Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety

ReachMD CME
25/03/2025 13 min

Listen "Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety "

Descargar episodio Ver en sitio original

Episode Synopsis

CME credits: 0.25
Valid until: 25-03-2026
Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/



When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need! =

More episodes of the podcast ReachMD CME

When Topicals Fail: The New IPC Consensus Every Clinician Should Know 22/12/2025
Hepatic Encephalopathy: More Common Than You Think 11/12/2025
A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies 26/11/2025
The Fifth Pillar? Closing the Gap in HFrEF 14/11/2025
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach 13/11/2025
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need 11/11/2025
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment 10/11/2025
Updates in Major Depressive Disorder with Insomnia 07/11/2025
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 05/11/2025
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD 31/10/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA